Rapport Reveals Pricing for Public Common Stock Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 09 2025
0mins
Source: Globenewswire
Public Offering Announcement: Rapport Therapeutics has priced an underwritten public offering of 9,615,385 shares of its common stock at $26.00 per share, aiming to raise approximately $250 million before expenses, with the offering expected to close around September 11, 2025.
Company Overview: Rapport Therapeutics is focused on developing small molecule precision medicines for neurological and psychiatric disorders, with its lead investigational drug, RAP-219, targeting conditions such as drug-resistant focal onset seizures and bipolar mania.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
